Tech Company Financing Transactions
Cambridge Epigenetix Funding Round
Temasek Holdings, Ahren Innovation Capital and GV joined a $88 million Series D funding round for Cambridge Epigenetix. The round was announced on 11/3/2021.
Transaction Overview
Company Name
Announced On
11/3/2021
Transaction Type
Venture Equity
Amount
$88,000,000
Round
Series D
Investors
Proceeds Purpose
Proceeds from the financing will be used to commercialize the company's proprietary genetic and epigenetic sequencing technology, which easily integrates into existing sequencing platforms to enable more information to be read from DNA.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
The Trinity Building Chesterford Research Park
Cambridge, CB10 1XL
UK
Cambridge, CB10 1XL
UK
Phone
Website
Email Address
Overview
Cambridge Epigenetix (CEGX) is a life sciences tools and analytics company that has created a technology platform delivering step changes in both the type of information that can be generated from DNA and the cost at which it is gathered.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Gail Marcus
Chief Financial Officer
Fiona Stewart
Founder
Shankar Balasubramanian
VP - Human Resources
Manuela Morgan
VP - R & D
Philippa Burns
VP - R & D
Joanna Holbrook
Browse more venture capital transactions:
Prev: 11/3/2021: Shoreline Biosciences venture capital transaction
Next: 11/3/2021: Magnify venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs